ClinicalTrials.Veeva

Menu

Tolerance Assesment of the Usage of an Analgesic Dose of Esketamine for Treatment of Moderate to Intense Pain in an Emergency Departement (ESKETAMINE)

A

Association pour la Formation l'Enseignement et la Recherche du Service de l'Accueil des Urgences

Status

Enrolling

Conditions

Pain, Acute

Treatments

Drug: Esketamine perfusion

Study type

Observational

Funder types

Other

Identifiers

NCT05666869
AFERSAU-2022-01

Details and patient eligibility

About

KETAMINE has been used for several years in emergency departments for analgesic purposes. Its ease of use and its analgesic effect have been demonstrated in several studies.

Nevertheless, this molecule is not devoid of side effects, in particular the very frequent occurrence of nausea, vomiting, anxiety, an overall feeling of discomfort and more rarely hallucinations, feelings of unreality, or tachycardia.

Recently, ESKETAMINE, used as an anesthetic but also in the USA as an antidepressant, has obtained its Marketing Authorization in the management of moderate to severe pain. ESKETAMINE corresponds to the S-(-)-KETAMINE enantiomer. Like KETAMINE, it acts as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor but unlike KETAMINE does not interact, with the sigma receptors responsible for hallucinations and delusional symptoms. ESKETAMINE aimed at anesthetic is about twice as potent as KETAMINE and would also be eliminated more quickly.

Studies suggest that at equivalent doses, ESKETAMINE would be better tolerated than the KETAMINE usually used in emergency departments.

In this study, the tolerance of ESKETAMINE used at analgesic doses for treatment of moderate to severe pain will be assessed in an emergency departement

A wider usage of ESKETAMINE for analgesia purpose in emergency departments is expected, with a better tolerance for the patients compared to KETAMINE

Enrollment

55 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age is 18 years old or more
  • Moderate to severe pain as assessed by the patient with a verbal numerical rating scale (NRS) of 6/10 or more ; NRS goes from 0 (no pain) to 10 (the worst pain imaginable)
  • Physician has decided to use ESKETAMINE
  • Patient is not opposed to enroll in the study after having been informed, as attested by the physician in the patient's file

Exclusion criteria

  • Adult under juridic protection, under guardianship, under curatorship
  • Patient unable to express his consent
  • Patient deprived of liberty by a judicial or administrative decision
  • Pregnant, parturient or nursing mother
  • Patients physically or mentally unable to answer the questionnaire
  • Typical kidney colic pain

Trial contacts and locations

1

Loading...

Central trial contact

Jocelyn Rapp, MSc; Julie Contenti, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems